Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 197

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 8
Chunk 197
---
 June 30,Six Months Ended June 30,(In thousands)2025202420252024Revenues:Product revenue, net$12,455 $8,615 $21,181 $16,804 Total revenue$12,455 $8,615 $21,181 $16,804 

Total Revenue - Three Months Ended June 30, 2025 vs. Three Months Ended June 30, 2024 – The increase in total revenue of $3.8 million for the three months ended June 30, 2025 compared to the three months ended June 30, 2024 was due to increased volume associated with PYRUKYND®.

Total Revenue - Six Months Ended June 30, 2025 vs. Six Months Ended June 30, 2024 – The increase in total revenue of $4.4 million for the six months ended June 30, 2025 compared to the six months ended June 30, 2024 was due to increased volume associated with PYRUKYND®.

Total Operating ExpensesThree Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Operating expenses:Cost of sales$1,702 $1,495 $2,787 $2,122 Research and development91,940 77,401 164,683 146,021 Selling, general and administrative45,869 35,536 87,396 66,550 Total operating expenses$139,511 $114,432 $254,866 $214,693 

Total Operating Expenses -  Three Months Ended June 30, 2025 vs. Three Months Ended June 30, 2024 – The increase in total operating expenses of $25.1 million for the three months ended June 30, 2025 compared to the three months ended June 30, 2024 was primarily due to an increase in research and development expenses of $14.5 million, which is described below under Research and Development Expenses, and an increase in selling, general and administrative expenses of $10.3 million, driven by an increase in commercial-related activities as we prepare for the potential approval of PYRUKYND® in thalassemia.

Total Operating Expenses -  Six Months Ended June 30, 2025 vs. Six Months Ended June 30, 2024 – The increase in total